-
Published: December, 2020Source: 62nd ASH Annual Meeting, Oral Abstract
Successful 24-hours manufacture of anti-CD19/CD22 dual chimeric antigen receptor (CAR) T cell therapy for B-cell acute lymphoblastic leukemia (B-ALL)
-
Published: December, 2020Source: 62nd ASH Annual Meeting, Oral Abstract
Clinical results of a multicenter study of the first-in-human dual BCMA and CD19 targeted novel platform Fast CAR-T cell therapy for patients with relapsed/refractory multiple myeloma
-
Published: October, 2020Source: Leukemia
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
-
Published: April, 2020Source: 2020 AACR Annual Meeting Abstract
Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)
-
Published: July, 2019Source: Medicine
Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two case reports
Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two case reports
